CD4 and neoplasm: Recently, we20–23 and others24,25 have shown that antigen-specific IL9-secreting (CD4+ Th9 or CD8+ Tc9) T cells are distinct subsets with stronger antitumor efficacy in murine tumor models compared to Th1, Th17, or Tc1/CTLs, respectively.